Full text is available at the source.
Abstract
Biosynthetic semaglutide may improve outcomes for adults with type 2 diabetes mellitus receiving routine outpatient care.
- The evaluation focuses on real-world effectiveness and safety in a cost-constrained setting.
- Patient-reported outcomes are also assessed to understand the treatment's impact on daily life.
- Findings could inform healthcare decisions regarding the use of biosynthetic semaglutide in routine care.
Simplified